238 related articles for article (PubMed ID: 17919823)
1. Treatments for metastatic melanoma: synthesis of evidence from randomized trials.
Lui P; Cashin R; Machado M; Hemels M; Corey-Lisle PK; Einarson TR
Cancer Treat Rev; 2007 Dec; 33(8):665-80. PubMed ID: 17919823
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients.
Ives NJ; Stowe RL; Lorigan P; Wheatley K
J Clin Oncol; 2007 Dec; 25(34):5426-34. PubMed ID: 18048825
[TBL] [Abstract][Full Text] [Related]
4. Systemic chemotherapy.
Klimek VM; Wolchok JD; Chapman PB; Houghton AN; Hwu WJ
Clin Plast Surg; 2000 Jul; 27(3):451-61, ix-x. PubMed ID: 10941565
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Ott PA; Chang JL; Oratz R; Jones A; Farrell K; Muggia F; Pavlick AC
Chemotherapy; 2009; 55(4):221-7. PubMed ID: 19451711
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy of malignant melanoma--current status].
Karg C; Garbe C; Orfanos CE
Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
[TBL] [Abstract][Full Text] [Related]
7. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
Eggermont AM; Kirkwood JM
Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
[TBL] [Abstract][Full Text] [Related]
8. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 for the treatment of melanoma.
Tarhini AA; Agarwala SS
Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
[TBL] [Abstract][Full Text] [Related]
11. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
McDermott DF; Sosman JA; Gonzalez R; Hodi FS; Linette GP; Richards J; Jakub JW; Beeram M; Tarantolo S; Agarwala S; Frenette G; Puzanov I; Cranmer L; Lewis K; Kirkwood J; White JM; Xia C; Patel K; Hersh E
J Clin Oncol; 2008 May; 26(13):2178-85. PubMed ID: 18445842
[TBL] [Abstract][Full Text] [Related]
12. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
13. The use of interferon alfa as adjuvant therapy for advanced cutaneous melanoma: the need for more evidence.
Kimyai-Asadi A; Usman A
J Am Acad Dermatol; 2000 Oct; 43(4):708-11. PubMed ID: 11004636
[TBL] [Abstract][Full Text] [Related]
14. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis.
Beguerie JR; Xingzhong J; Valdez RP
Int J Dermatol; 2010 Oct; 49(10):1194-202. PubMed ID: 20883410
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone].
Chauvergne J; Bui NB; Cappelaere P; Gary-Bobo J; Guerrin J; Armand JP; Durand M
Sem Hop; 1982 Dec; 58(46):2697-701. PubMed ID: 6297068
[TBL] [Abstract][Full Text] [Related]
16. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Glaspy J; Atkins MB; Richards JM; Agarwala SS; O'Day S; Knight RD; Jungnelius JU; Bedikian AY
Cancer; 2009 Nov; 115(22):5228-36. PubMed ID: 19728370
[TBL] [Abstract][Full Text] [Related]
17. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
[TBL] [Abstract][Full Text] [Related]
18. [In vitro drug sensitivity profiling in melanoma].
Ugurel S
J Dtsch Dermatol Ges; 2008 Jul; 6(7):611. PubMed ID: 18611186
[No Abstract] [Full Text] [Related]
19. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for metastatic melanoma.
Mandarà M; Nortilli R; Sava T; Cetto GL
Expert Rev Anticancer Ther; 2006 Jan; 6(1):121-30. PubMed ID: 16375649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
